---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-044043"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T10:39:10.285532+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharmaceuticals completes acquisition of Renovacor; gains BAG3-DCM gene therapy REN-001

## Summary
- Renovacor shareholders received 0.1763 shares of Rocket common stock per Renovacor share.
- Acquisition extends Rocket's AAV-based cardiac gene therapy leadership with REN-001 targeting BAG3-associated dilated cardiomyopathy.
- Rocket gains Renovacor's IP, scientific collaborators, and BAG3-DCM expertise.
- Renovacor shares ceased trading on NYSE; Rocket continues on Nasdaq as RCKT.
- Stockholders approved the share issuance proposal at Nov 30 special meeting with ~99.9% votes for.

## SEC filing metadata
- accession: 0001140361-22-044043
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036122044043/0001140361-22-044043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036122044043/brhc10044894_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-044043
- JSON: https://secwatch.observer/filing/0001140361-22-044043.json
- Plain text: https://secwatch.observer/filing/0001140361-22-044043.txt

## Key facts
- M&A Transactions
  ROCKET PHARMACEUTICALS, INC. completed an acquisition involving Renovacor, Inc. (closed 2022-12-01).
  - Action: acquisition
  - Counterparty: Renovacor, Inc.
  - Closing: 2022-12-01
  source text: On December 1, 2022, pursuant to the terms of the Merger Agreement, (i) Merger Sub I merged with and into the Company (the “First Merger”) and (ii) the Company, as the surviving company of the First Merger, merged with and into Merger Sub II (the “Second Merger” and together with the First Merger, the “Mergers”), with Merger Sub II surviving the Mergers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036122044043/0001140361-22-044043-index.htm
- Shareholder Votes
  ROCKET PHARMACEUTICALS, INC. shareholders approved To approve the issuance of Parent Shares to security holders of Renovacor, as contemplated by the Merger Agreement pursuant to Nasdaq Rule 5635(a)(2) at the 2022-11-30 meeting.
  - Proposal: merger approval
  - Outcome: passed
  - Meeting: 2022-11-30
  source text: Rocket Share Issuance Proposal . To vote to approve the issuance of Parent Shares to security holders of Renovacor, as contemplated by the Merger Agreement pursuant to Nasdaq Rule 5635(a)(2) (the “Rocket Share Issuance Proposal”). Votes For Votes Against Abstentions 58,919,928 45,017 51,950
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036122044043/0001140361-22-044043-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.